Companies›Healthcare›Healthcare›Pharmaceuticals & Biotechnology

GUJARAT INJECT (KERALA) LTD.

Healthcare › Pharmaceuticals & Biotechnology
₹10.65
at close · 27 Oct 2026
▲ 0.55 (+5.45%)
ThemesSolar Energy· growingBatteries & Energy Storage· announcedElectric Vehicles· announced

Latest filings

  1. Board to consider preferential issue of shares and warrants · Fund Raising
  2. Board to consider preferential share and warrant issue · Fund Raising
  3. Gujarat Inject Kerala Bags Rs 6.25 Crore Solar Module Order from Deon Energy · Business Updates
All filings ↓
Ask Nexa about GUJARAT INJECT (KERALA) LTD.

Snapshot

What the business is, and whether it's a good one at a fair price.

AI · written from filings

Sells solar PV modules to private domestic buyers and operates a 5 MW solar project in Jakasana, Gujarat. The company, formerly pharmaceutical-focused, is pivoting to renewable energy and has proposed renaming itself Regenova Renewtech Limited. FY26 revenue was Rs. 36.32 crore, up 91% year-on-year, with new solar activity reported at 77% of revenue. Solar PV module orders booked during FY26 include about Rs. 14.49 crore from Deon Energy for 16,129 modules of 620 WP, Rs. 3.49 crore from Earthwave Technology for 4,056 modules, Rs. 3.11 crore from Earthwave Technology for 3,645 modules, Rs. 1.21 crore from Perfect Renewtech for 1,355 modules, and Rs. 1.07 crore from Ottrive Lifestyle for 1,334 modules of 600 WP. Q1 FY27 revenue rose 414% year-on-year to Rs. 12.45 crore. The business operates as a single reportable segment with very low employee and other operating costs (Rs. 0.18 crore and Rs. 0.21 crore respectively in FY26) and heavy capex of Rs. 20.76 crore (57.2% of revenue) tied to the renewable-energy shift.

Revenue mix · reported segments
Solar PV modules and related trading77.0%
Legacy / residual business23.0%
Operating scale
Solar project capacity
5 MWFY26
Solar project location
Jakasana, GujaratFY26
Deon Energy order
16,129 Solar PV Modules (620 WP), ~Rs. 14.49 croreFY26
Earthwave Technology orders
4,056 + 3,645 Solar PV Modules (~Rs. 3.49 crore + Rs. 3.11 crore)FY26
Perfect Renewtech order
1,355 Solar PV Modules (GS12R-T132-GF-620WP), ~Rs. 1.21 croreFY26
Ottrive Lifestyle order
1,334 Solar PV Modules (600 WP), ~Rs. 1.07 croreFY26
Who pays it
Private domestic buyers of solar PV modules, including Deon Energy, Earthwave Technology, Perfect Renewtech and Ottrive Lifestyle.
Biggest cost
Capex tied to the renewable-energy pivot at Rs. 20.76 crore (57.2% of FY26 revenue); employee and other operating costs are minimal.
Kind of business
Small, trading-heavy solar PV module seller pivoting from pharmaceuticals into renewable energy.
Where it sits
Early-stage entrant in solar PV module supply with a 5 MW project in Jakasana, Gujarat, rebranding to Regenova Renewtech Limited.
Market Cap
₹16 Cr
P / E (TTM)
4.5×
EV / EBITDA
6.0×
Div Yield
—
Growth
401.1%▲
Revenue 5y CAGR
PAT — · EBITDA +237.7%
Quality
n/m·
ROCE · capital employed below zero
ROE n/m · margin 6.9%
Leverage
0.00·
Debt / Equity · low
Net cash ₹0.68 Cr
Revenue FY21→FY26
3158.3×▲
Margin +919.8 pts
₹0 Cr → ₹36 Cr
Cash conversion
4.06×▲
Operating cash ÷ profit · 5 yrs
₹12 Cr on ₹3 Cr
Moves on a normal day
3.39%·
Median daily move
Last 79 sessions · the yardstick for filing-day moves
Where it sits among 185 Pharmaceuticals peersBar = share of peers beaten · tick = industry median · latest reported figures
P/E (TTM)#7/158
P/B#37/163
ROCE#31/183
ROE#46/166
Debt / Equity#1/166
EBITDA margin#133/165
Revenue growth#1/161
Profit growth#3/158

Scorecard

Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice

Strengths
Revenue compounding 401% a year over 5 years
Profit grew in every one of the last 5 years
No borrowings on the balance sheet
lower than 79% of its 166 Pharmaceuticals peers
Over 5 years it reported ₹2.96 Cr of profit and ₹12 Cr of operating cash — 4.06×
Profit is converting into cash
Negative working-capital cycle — the business is funded by its suppliers
Concerns
Nothing flagged in the filed numbers.

Charts

How has the market priced it — with filings on the timeline?

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Peers

How does it stack up on valuation, returns and growth?

Loading peers…

Financials

Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.

Loading financials…

Ownership

Who owns it — and is the promoter stake clean?

Loading shareholding…

Sign up to see the full company file

Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.

Common questions

Answered from GUJARAT INJECT (KERALA) LTD.'s filed financials and exchange disclosures

What does GUJARAT INJECT (KERALA) LTD. do?

GUJARAT INJECT (KERALA) LTD. is a Pharmaceuticals & Biotechnology company listed on BSE.

Is GUJARAT INJECT (KERALA) LTD. profitable?

Yes. Over the trailing twelve months GUJARAT INJECT (KERALA) LTD. reported a net profit of ₹1.81 Cr on revenue of ₹36 Cr.

Does GUJARAT INJECT (KERALA) LTD. pay a dividend?

Not in the latest reported year — GUJARAT INJECT (KERALA) LTD.'s dividend payout for FY26 was nil.

Is GUJARAT INJECT (KERALA) LTD. debt-free?

Yes. It reported no borrowings on its 31 Mar 2026 balance sheet, and ₹0.68 Cr of cash.

Is GUJARAT INJECT (KERALA) LTD. expensive compared with its peers?

On trailing P/E, GUJARAT INJECT (KERALA) LTD. ranks 7 of 158 in Pharmaceuticals — cheaper than 96% of them, against an industry median of 30.1×. This is a position, not a valuation judgement.

How much does the GUJARAT INJECT (KERALA) LTD. share price move in a day?

On a typical session GUJARAT INJECT (KERALA) LTD. moves 3.39% — that is the median absolute close-to-close move across its last 79 trading days. MarketPing measures each filing's price reaction against it.

Where can I track GUJARAT INJECT (KERALA) LTD.'s announcements?

Every NSE and BSE filing by GUJARAT INJECT (KERALA) LTD. appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.

Figures are as last reported and may lag the latest filing. Not investment advice.